
    
      This will be an open-label, phase I study. This study will evaluate the safety and
      pharmacokinetics of HMPL-013 after a single administration followed by a 28-Day continuous
      course of therapy; evaluate the safety and preliminary efficacy in an open-label
      administration of at the MTD. All subjects of this study will be permitted to continue
      therapy with only safety monitoring and bimonthly assessments for progression, if the product
      is well tolerated and the subject has stable disease or better.
    
  